Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells.
Explore this paper's citation graph
Summary
Different mechanisms determineAPL uptake and consequent apoptotic toxicity in lymphoma versus carcinoma cells, in the latter cells, APL uptake is mainly determined by a raft- and endocytosis-independent process, but metabolic energy-dependent process, possibly by a lipid transporter.
- Type
- article
- Published
- 2007-11-15
- Cited by
- 40
- References
- 46
- OpenAlex
- https://openalex.org/W17803969
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:26093611
Keywords
Computer science
References
- Signalling steps in apoptosis by ether lipids
- Cellular uptake and metabolic fate of hexadecylphosphocholine.
- Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells.
- Antitumoral activity of alkylphosphocholines and analogues in human leukemia cell lines.
- Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells.
- Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling.
- A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry.
- Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities.
- Phospholipid Translocation and Miltefosine Potency Require Both L. donovani Miltefosine Transporter and the New Protein LdRos3 in Leishmania Parasites*
- Synergistic cytotoxic effects of ether phospholipid analogues and ionizing radiation in human carcinoma cells.
- Facilitated phosphatidylcholine flip-flop across erythrocyte membranes using low molecular weight synthetic translocases.
- Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts.
- Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB.
- Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy.
- Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
- Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid
- Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
- D-21266, a new heterocyclic alkylphospholipid with antitumour activity.
- Uptake and Utilization of Lyso-phosphatidylethanolamine by Saccharomyces cerevisiae*
- Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis.
Cited by
- Fas/CD95 down-regulation in lymphoma cells through acquired alkyllysophospholipid resistance: partial role of associated sphingomyelin deficiency.
- Disruption of cellular cholesterol transport and homeostasis as a novel mechanism of action of membrane‐targeted alkylphospholipid analogues
- Wirksamkeit und Verträglichkeit des Raft-Interventionstherapeutikums Miltefosin bei der Behandlung der kutanen Mastozytose
- Heparin and Suramin Alter Plitidepsin Uptake Via Inhibition of GPCR Coupled Signaling
- CDC50A plays a key role in the uptake of the anticancer drug perifosine in human carcinoma cells.
- Silencing of anti-apoptotic transmembrane protein lifeguard sensitizes solid tumor cell lines MCF-7 and SW872 to perifosine-induced cell death activation.
- Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects.
- Influence of cancerostatic perifosine on membrane fluidity of liposomes and different cell lines as measured by electron paramagnetic resonance
- Perifosine: Update on a Novel Akt Inhibitor
- Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double‐blind, placebo‐controlled trial
- Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine.
- Synthesis and antitumor activity of 3-[(methyl)bis(5-trialkylsilyl-furan-2-yl)silyl]propylamines
- Anticancer mechanisms and clinical application of alkylphospholipids.
- Interactions of anticancer drugs with biomembranes: what can we learn from model membranes?
- Edelfosine and miltefosine effects on lipid raft properties: membrane biophysics in cell death by antitumor lipids.
- Synthesis and cytotoxic activity of new 2-[(3-aminopropyl)dimethylsilyl]-5-triethylsilylfurans
- Sphingomyelin synthase 2 (SMS2) deficiency attenuates LPS-induced lung injury.
- A critical role of c-Cbl-interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the ras-ERK pathway.
- Combining anti-tumor alkyl-phospholipid analogs and radiotherapy: rationale and clinical outlook.
- The membrane-targeted alkylphosphocholine erufosine interferes with survival signals from the extracellular matrix.
Related papers
No related papers recorded.